As many gather to celebrate the joyous holiday season, “spirits” (those of both the emotional and alcoholic persuasions) are sure to flow. But if you have Covid-19 ---- you may just want to hold off on those wines, beers, and cocktails.

RSV (respiratory syncytial virus) is a term many physicians have known for years, and most have largely ignored. Until approximately 3 years ago, unless you were an Emergency Medicine Physician like me or in a pediatrics related field, RSV was essentially irrelevant.

There are some lone rangers out there that haven’t yet caught the SARS-CoV-2 virus. Are they Super-Dodgers, Novids, Covid Virgins or Never Covids?

Well, the holidays are just around the corner and very soon many of us will be at each other’s homes gathering with loved ones, expressing our thanks while we indulge in turkey and all the usual festive fixings.

Access to high-quality healthcare can be challenging. The COVID-19 pandemic really shone a light on the health inequities within indigenous communities due to under-funded and under-resourced health systems with limited services, supplies, staffing, and infrastructure.

Pharmacies played a crucial role in providing essential healthcare solutions to their communities during the Covid-19 pandemic.

A forecast from the US Centers for Disease Control and Prevention indicates this respiratory disease season will once again be similar to last year, which saw hospital beds more full than during the pandemic and pre-pandemic years.

As a healthcare provider, you are presented with multiple options for SARS-CoV-2 (COVID-19) testing. The choice between send-out/lab-based PCR, rapid antigen tests, or various Nucleic Acid Amplification Test (NAAT) Point-of-Care (POC) methodologies depends on what best fits your facility's needs and ensures optimal patient treatment.

Have you wondered how the COVID-19 variants got their names? I did not until Omicron came around, when I thought, ‘why is each variant a never-ending alphabet soup only a scientist could love’? Or, ‘why don’t we have more menacing names like Vader or Khan’??

The recent late-summer COVID infection surge has triggered interest from an unlikely segment of the population: plaintiff’s lawyers.

A recent article in Skilled Nursing News revealed that according to AARP, during the four weeks ending on August 20, 2023, the rate of COVID-19 resident deaths increased by 80% compared to the prior four weeks in July 2023.

In recent months, there may have been limited attention towards the stock and expiration dates of COVID-19 testing kits. It's crucial to assess and replenish these resources. For those utilizing the Accula dock and the associated COVID-19 test, it is pertinent to note that Thermo Fisher ceased production in April.

Why is the Anavasi Diagnostics platform a great solution for affordable and accurate point-of-care COVID-19 testing? Here is a scientist’s (not salesperson’s) take on it.

Why would somebody need to keep testing a test designed to detect Covid-19 infection? It either worked or it didn’t when the FDA approved it and hopefully, they did not approve a test that does not detect the virus…

This past summer, you may not have thought much about COVID-19 or your testing supplies, correct? In the wake of this latest surge, you may now be reaching for your supply shelf and realizing you need to restock COVID tests. Well, if you are a former Accula™ user you may be in for a shock.

In September 2020, the CDC launched the National Wastewater Surveillance System (NWSS) to monitor SARS-CoV-2 in wastewater and has invested over $100M in its infrastucture.² Since its inception over 1000 testing sites have come on board providing screening data of approximately 130 million people nationwide.

Yes – COVID-19 is on the rise again and that is thanks mostly in part to the latest variant EG.5. Nicknamed Eris, this latest strain, according to genetic sequencing, appears to be related to Omicron subvariant called XBB.1.9.2.

A few weeks ago, we saw signs that a summertime wave of COVID-19 was starting to usher in.

Despite the reprieve offered by the summer season, it is important for healthcare professionals to be mindful of the approaching respiratory season.

On April 11, 2023, Thermo Fisher Scientific announced it will discontinue the manufacturing and direct sales of the Thermo Fisher Accula™ line of products by April 26, 2023.